# Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania

Study · id `cardio:ct-nct06704633` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06704633](<https://clinicaltrials.gov/study/NCT06704633>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06704633

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 298 participants.

## Technical summary

Registry record NCT06704633. Allocation not applicable; no masking; primary purpose treatment. Start 2026-06-30 (actual); primary completion 2028-11-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 298 participants (planned count; ClinicalTrials.gov record NCT06704633, source copy `cardio:ctgov-nct06704633-2026-07-02`, retrieved 2026-10-26)
- Started: 2026-06-30 (actual) (ClinicalTrials.gov record NCT06704633, source copy `cardio:ctgov-nct06704633-2026-07-02`, retrieved 2026-10-26)
- Primary completion: 2028-11-30 (anticipated) (ClinicalTrials.gov record NCT06704633, source copy `cardio:ctgov-nct06704633-2026-07-02`, retrieved 2026-10-26)
- Completion: 2028-11-30 (anticipated) (ClinicalTrials.gov record NCT06704633, source copy `cardio:ctgov-nct06704633-2026-07-02`, retrieved 2026-10-26)
- Countries: Tanzania (ClinicalTrials.gov record NCT06704633, source copy `cardio:ctgov-nct06704633-2026-07-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06704633-2026-07-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania
- Condition: Heart Failure
- Intervention (Drug): Sacubitril / Valsartan Oral Tablet
- Lead sponsor: Martin Rohacek
- Lead sponsor class: OTHER
- Collaborator: Ifakara Health Institute
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Sacubitril/valsartan (combination) (`cardio:sacubitril-valsartan`)

## Provenance

Content hash: 9b5c4c4c05e8beb4f184e9700e11b19379ac52f897f81ca565a7d10f0f3a2ddc
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
